article · Journal of clinical lipidology
Ezetimibe, in combination with high-intensity statin therapy, significantly reduces LDL-C levels in patients with genotypically confirmed HoFH. However, the response to ezetimibe is highly variable and unpredictable across genotypes. This study supports the inclusion of ezetimibe in the treatment regimen for all HoFH patients to reduce the risk of ASCVD. Further studies are needed to understand the variable responses to ezetimibe among different genotypes and in HoFH individuals with the same genotype.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.jacl.2024.11.003
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
